Press release
Stable Angina Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Stable Angina Overview
Angina is chest pain or discomfort occurs when required oxygen demand of the myocardium cannot be met. It is a prominent symptom of an underlying heart problem, usually coronary heart disease (CHD), or coronary artery disease (CAD). Patients with stable angina usually know the level of activity or stress that brings on an attack.
"Stable Angina Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Stable Angina Market.
The Stable Angina Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Stable Angina Pipeline Report: https://www.delveinsight.com/report-store/chronic-stable-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Stable Angina treatment therapies with a considerable amount of success over the years. Stable Angina Key players such as - Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others, are developing therapies for the Stable Angina treatment
• Stable Angina Emerging therapies such as - T89, AR36, and others are expected to have a significant impact on the Stable Angina market in the coming years.
Stable Angina Pipeline Therapeutics Assessment
• Stable Angina Assessment by Product Type
• Stable Angina By Stage and Product Type
• Stable Angina Assessment by Route of Administration
• Stable Angina By Stage and Route of Administration
• Stable Angina Assessment by Molecule Type
• Stable Angina by Stage and Molecule Type
DelveInsight's Stable Angina Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Some of the key companies in the Stable Angina Therapeutics Market include:
Key Companies developing therapies for Stable Angina treatment are - Pfizer Inc., AstraZeneca PLC, Merck & Co., Inc., Novartis International AG, Sanofi S.A., Bayer AG, GlaxoSmithKline PLC, Abbott Laboratories, Eli Lilly and Company, Bristol-Myers Squibb Company, and others
Emerging Stable Angina Drugs Under Different Phases of Clinical Development Include:
• T89: Tasly Pharmaceuticals
• AR36: Arbor Pharmaceuticals
Get a Free Sample PDF Report to know more about Stable Angina Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/chronic-stable-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Stable Angina Pipeline Analysis:
The Stable Angina pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Stable Angina with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stable Angina Treatment.
• Stable Angina key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Stable Angina Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Stable Angina market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Stable Angina product details are provided in the report. Download the Stable Angina pipeline report to learn more about the emerging Stable Angina therapies at:
https://www.delveinsight.com/sample-request/chronic-stable-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of Stable Angina Pipeline Drug Insight
• Coverage: Global
• Key Stable Angina Companies: Tasly Pharmaceuticals, Arbor Pharmaceuticals, and others
• Key Stable Angina Therapies: T89, AR36, and others
• Stable Angina Therapeutic Assessment: Stable Angina current marketed and Stable Angina emerging therapies
• Stable Angina Market Dynamics: Stable Angina market drivers and Stable Angina market barriers
Request for Sample PDF Report for Stable Angina Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/chronic-stable-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Stable Angina Report Introduction
2 Stable Angina Executive Summary
3 Stable Angina Overview
4 Stable Angina- Analytical Perspective In-depth Commercial Assessment
5 Stable Angina Pipeline Therapeutics
6 Stable Angina Late Stage Products (Phase II/III)
7 Stable Angina Mid Stage Products (Phase II)
8 Stable Angina Early Stage Products (Phase I)
9 Stable Angina Preclinical Stage Products
10 Stable Angina Therapeutics Assessment
11 Stable Angina Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Stable Angina Key Companies
14 Stable Angina Key Products
15 Stable Angina Unmet Needs
16 Stable Angina Market Drivers and Barriers
17 Stable Angina Future Perspectives and Conclusion
18 Stable Angina Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Stable Angina drugs and therapies- https://www.delveinsight.com/sample-request/chronic-stable-angina-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Stable Angina Market https://www.delveinsight.com/report-store/stable-angina-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Stable Angina-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Stable Angina Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2931230 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Angina
Surging Prevalence Of Cardiovascular Diseases Propels Growth In The Angina Pecto …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Angina Pectoris Drugs Market Size By 2025?
The market size for angina pectoris drugs has experienced consistent growth in the past few years. The market is projected to expand from $12.32 billion in 2024 to $12.88 billion in 2025, representing a compound annual growth rate…
Angina (Angina Pectoris) Pipeline: 10+ Companies Transforming Chest Pain Managem …
The angina therapeutics pipeline is experiencing a renaissance, driven by pharmaceutical companies such as Abbott Laboratories, AstraZeneca, Bayer AG, and Bristol-Myers Squibb. With a focus on improving myocardial efficiency and reducing ischemic burden, emerging therapies-including metabolic modulators, nitric oxide donors, and gene therapies-aim to offer more effective symptom relief and reduce cardiovascular events. Innovations are targeting both stable and microvascular angina forms, addressing the significant unmet needs in chronic angina…
What's Driving the Angina Market 2025-2034: The Rising Prevalence of Coronary Ar …
What Are the Projections for the Size and Growth Rate of the Angina Market?
The scale of the angina market has seen robust growth in the previous years. The expansion is expected to continue, increasing from a value of $10.71 billion in 2024 to $11.4 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.4%. The surge in the past period can be credited to factors such as a…
Angina Pectoris - Drug Pipeline Landscape, 2022
Global Angina Pectoris Market report from Global Insight Services is the single authoritative source of intelligence on angina pectoris market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Angina Pectoris - Drug Pipeline Landscape, 2022
Angina also known as angina pectoris, is a type of chest pain or discomfort that occurs when a part of the heart doesn't get enough blood and oxygen, which is due to the spasm or obstruction of the arteries that supply the blood to the heart muscles. Angina is mainly of four types: stable angina, unstable angina, microvascular angina, and vasospastic or variant angina.
Angina is caused due to the built…
Angina Pectoris Drugs Market Set for Rapid Growth
Global Angina Pectoris Drugs Market: Overview
The demand within the global market for angina pectoris drugs has been rising on account of the focus given on treating medical conditions suffered by the geriatric population. The presence of a seamless industry for healthcare diagnostic and treatment has played a major role in market growth. Angina pectoris is a type of chest pain that is triggered due to reduced blood flow to…
